InvestSMART

Pro Medicus Limited (ASX:PME)

ALERT: Price-sensitive ASX Announcement for PME
Current share price for PME : $175.730 -0.13 (-0.07%)+
Announcement
Release
18 Aug 2026 9:32AM
Price at Release
$175.860
Full Release
download
Summary
Pro Medicus Limited (PME) reported robust financial results for the fiscal year ending 30 June 2026. The company achieved a 24.1% increase in underlying net profit after tax (NPAT), amounting to $144.7 million, and a significant increase in reported NPAT of 130.3% to $265.3 million. Revenue from ordinary activities grew by 22.9% to $261.7 million, with cash and financial assets rising by 19.7% to $252.3 million. PME remains debt-free and declared a fully-franked final dividend of 37 cents per share, totaling 69 cents for the year, up 25.5%. On a constant currency basis, revenues increased by 28.4%, and underlying EBIT and NPAT rose by 30.6% and 32.5%, respectively. The company signed new contracts worth $407 million and renewed contracts valued at $141 million. The CEO, Dr. Sam Hupert, emphasized the strong performance and customer confidence reflected in the results, highlighting the expansion in the cardiology market and the record number of contract renewals.
Key Points
  • Pro Medicus Limited reported a 24.1% increase in underlying NPAT.
  • Reported NPAT increased by 130.3% to $265.3 million.
  • Revenue grew by 22.9% to $261.7 million.
  • The company remains debt-free with cash assets up 19.7%.
  • Fully-franked final dividend of 37 cents per share.
  • Constant currency revenue increased by 28.4%.
  • Signed new contracts worth $407 million and renewals of $141 million.
  • Strong performance noted in the cardiology market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.